The loan will help Resilience achieve its goal of establishing significant domestic, end-to-end biomanufacturing capacity and capabilities for biologics (antibodies, proteins, multi-specifics), vaccines, and nucleic acids (including mRNA). Together with existing technology and capabilities across Resilience’s biomanufacturing network, this expanded capacity will help secure the nation’s supply chain for vaccines and critical medicines, strengthen pandemic preparedness and response, and address a critical advanced manufacturing infrastructure shortage revealed by the COVID-19 pandemic.
Part of the funding will go toward the implementation of innovative manufacturing platforms and technologies aimed at lowering costs, strengthening the domestic supply chain, and increasing vaccine supply speed.
Resilience is a biomanufacturing company focused on technology that is dedicated to increasing access to complex medicines (biologics, vaccines, nucleic acid, cell therapy, and gene therapy modalities). Founded in 2020, the company is establishing a long-term network of high-tech, end-to-end manufacturing solutions to ensure that today’s and tomorrow’s treatments can be produced quickly, safely, and at scale.
Resilience seeks to free its partners to focus on discoveries that improve patients’ lives and protect biopharmaceutical supply chains from future disruptions by continuously advancing the science of biopharmaceutical manufacturing and development.
